Literature DB >> 25057108

Isolation of a circulating CD45-, CD34dim cell population and validation of their endothelial phenotype.

Margaret M Tropea, Bonnie J A Harper, Grace M Graninger, Terry M Phillips, Gabriela Ferreyra, Howard S Mostowski, Robert L Danner, Anthony F Suffredini, Michael A Solomon1.   

Abstract

Accurately detecting circulating endothelial cells (CECs) is important since their enumeration has been proposed as a biomarker to measure injury to the vascular endothelium. However, there is no single methodology for determining CECs in blood, making comparison across studies difficult. Many methods for detecting CECs rely on characteristic cell surface markers and cell viability indicators, but lack secondary validation. Here, a CEC population in healthy adult human subjects was identified by flow cytometry as CD45-, CD34dim that is comparable to a previously described CD45-, CD31bright population. In addition, nuclear staining with 7-aminoactinomycin D (7-AAD) was employed as a standard technique to exclude dead cells. Unexpectedly, the CD45-, CD34dim, 7-AAD- CECs lacked surface detectable CD146, a commonly used marker of CECs. Furthermore, light microscopy revealed this cell population to be composed primarily of large cells without a clearly defined nucleus. Nevertheless, immunostains still demonstrated the presence of the lectin Ulex europaeus and von Willebrand factor. Ultramicro analytical immunochemistry assays for the endothelial cell proteins CD31, CD34, CD62E, CD105, CD141, CD144 and vWF indicated these cells possess an endothelial phenotype. However, only a small amount of RNA, which was mostly degraded, could be isolated from these cells. Thus the majority of CECs in healthy individuals as defined by CD45-, CD34dim, and 7-AAD- have shed their CD146 surface marker and are senescent cells without an identifiable nucleus and lacking RNA of sufficient quantity and quality for transcriptomal analysis. This study highlights the importance of secondary validation of CEC identification.

Entities:  

Keywords:  Vascular cell markers; circulating endothelial cells; flow cytometry; gene expression; viability

Mesh:

Substances:

Year:  2014        PMID: 25057108      PMCID: PMC4988526          DOI: 10.1160/TH14-01-0043

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  39 in total

1.  A new approach for rapid and reliable enumeration of circulating endothelial cells in patients.

Authors:  J Kraan; M H Strijbos; A M Sieuwerts; J A Foekens; M A den Bakker; C Verhoef; S Sleijfer; J W Gratama
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

2.  CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood.

Authors:  Mohamed F Elshal; Sameena S Khan; Yoshiyuki Takahashi; Michael A Solomon; J Philip McCoy
Journal:  Blood       Date:  2005-10-15       Impact factor: 22.113

3.  Cells meeting our immunophenotypic criteria of endothelial cells are large platelets.

Authors:  Michiel H Strijbos; Jaco Kraan; Michael A den Bakker; Bart N Lambrecht; Stefan Sleijfer; Jan W Gratama
Journal:  Cytometry B Clin Cytom       Date:  2007-03       Impact factor: 3.058

4.  CD146 and its soluble form regulate monocyte transendothelial migration.

Authors:  Nathalie Bardin; Marcel Blot-Chabaud; Nicolas Despoix; Abdeldjalil Kebir; Karim Harhouri; Jean-Pierre Arsanto; Leon Espinosa; Pierre Perrin; Stéphane Robert; Frédéric Vely; Florence Sabatier; André Le Bivic; Gilles Kaplanski; José Sampol; Françoise Dignat-George
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-02-19       Impact factor: 8.311

5.  Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial.

Authors:  D Janssens; C Michiels; G Guillaume; B Cuisinier; Y Louagie; J Remacle
Journal:  J Cardiovasc Pharmacol       Date:  1999-01       Impact factor: 3.105

Review 6.  Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use.

Authors:  Gian Paolo Fadini; Douglas Losordo; Stefanie Dimmeler
Journal:  Circ Res       Date:  2012-02-17       Impact factor: 17.367

7.  Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration.

Authors:  Nathalie Bardin; Valérie Moal; Francine Anfosso; Laurent Daniel; Philippe Brunet; José Sampol; Françoise Dignat George
Journal:  Thromb Haemost       Date:  2003-11       Impact factor: 5.249

8.  Circulating endothelial cells in acute myocardial infarction and angina pectoris.

Authors:  J Hladovec; I Prerovský; V Stanĕk; J Fabián
Journal:  Klin Wochenschr       Date:  1978-10-15

9.  A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.

Authors:  Dan G Duda; Kenneth S Cohen; David T Scadden; Rakesh K Jain
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

10.  Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction.

Authors:  Jian Ye; George Coulouris; Irena Zaretskaya; Ioana Cutcutache; Steve Rozen; Thomas L Madden
Journal:  BMC Bioinformatics       Date:  2012-06-18       Impact factor: 3.169

View more
  2 in total

Review 1.  Comprehensive phenotyping of endothelial cells using flow cytometry 2: Human.

Authors:  Dillon Grant; Nicholas Wanner; Matthew Frimel; Serpil Erzurum; Kewal Asosingh
Journal:  Cytometry A       Date:  2020-12-23       Impact factor: 4.714

2.  Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness.

Authors:  Qianjun Zhou; Qing Geng; Lin Wang; Jia Huang; Meilin Liao; Yan Li; Zhengping Ding; Shentu Yang; Hang Zhao; Qiang Shen; Changqing Pan; Jiatao Lou; Shun Lu; Chang Chen; Qingquan Luo
Journal:  EBioMedicine       Date:  2019-03-12       Impact factor: 8.143

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.